Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
@prefix fhir: <http://hl7.org/fhir/> . @prefix owl: <http://www.w3.org/2002/07/owl#> . @prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> . @prefix xsd: <http://www.w3.org/2001/XMLSchema#> . # - resource ------------------------------------------------------------------- a fhir:Bundle ; fhir:nodeRole fhir:treeRoot ; fhir:id [ fhir:v "bundlepackageleaflet-en-cfcde91a66ec9c44e54756602bc42482"] ; # fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"^^xsd:anyURI ; fhir:link <http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi> ] ) ] ; # fhir:language [ fhir:v "en"] ; # fhir:identifier [ fhir:system [ fhir:v "http://ema.europa.eu/identifier"^^xsd:anyURI ] ; fhir:value [ fhir:v "None" ] ] ; # fhir:type [ fhir:v "document"] ; # fhir:timestamp [ fhir:v "2023-06-27T10:09:22Z"^^xsd:dateTime] ; # fhir:entry ( [ fhir:fullUrl [ fhir:v "Composition/composition-en-cfcde91a66ec9c44e54756602bc42482"^^xsd:anyURI ] ; ( fhir:resource <Composition/composition-en-cfcde91a66ec9c44e54756602bc42482> ) ] [ fhir:fullUrl [ fhir:v "MedicinalProductDefinition/mpcfcde91a66ec9c44e54756602bc42482"^^xsd:anyURI ] ; ( fhir:resource <MedicinalProductDefinition/mpcfcde91a66ec9c44e54756602bc42482> ) ] ) . # <Composition/composition-en-cfcde91a66ec9c44e54756602bc42482> a fhir:Composition ; fhir:id [ fhir:v "composition-en-cfcde91a66ec9c44e54756602bc42482"] ; # fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"^^xsd:anyURI ; fhir:link <http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi> ] ) ] ; # fhir:language [ fhir:v "en"] ; # fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-cfcde91a66ec9c44e54756602bc42482\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-cfcde91a66ec9c44e54756602bc42482</b></p><a name=\"composition-en-cfcde91a66ec9c44e54756602bc42482\"> </a><a name=\"hccomposition-en-cfcde91a66ec9c44e54756602bc42482\"> </a><a name=\"composition-en-cfcde91a66ec9c44e54756602bc42482-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/19/1376/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - libtayo</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>" ] ; # fhir:identifier ( [ fhir:system [ fhir:v "http://ema.europa.eu/identifier"^^xsd:anyURI ] ; fhir:value [ fhir:v "EU/1/19/1376/001" ] ] ) ; # fhir:status [ fhir:v "final"] ; # fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "Package Leaflet" ] ] ; # fhir:category ( [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"^^xsd:anyURI ] ; fhir:code [ fhir:v "R" ] ; fhir:display [ fhir:v "Raw" ] ] ) ] ) ; # fhir:subject ( [ fhir:reference [ fhir:v "MedicinalProductDefinition/mpcfcde91a66ec9c44e54756602bc42482" ] ] ) ; # fhir:date [ fhir:v "2022-02-16T13:28:17Z"^^xsd:dateTime] ; # fhir:author ( [ fhir:reference [ fhir:v "Organization/mah-ema" ] ] ) ; # fhir:title [ fhir:v "TEST PURPOSES ONLY - libtayo"] ; # fhir:attester ( [ fhir:mode [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/composition-attestation-mode"^^xsd:anyURI ] ; fhir:code [ fhir:v "official" ] ] ) ] ; fhir:time [ fhir:v "2022-02-16T13:28:17Z"^^xsd:dateTime ] ] ) ; # fhir:section ( [ fhir:title [ fhir:v "B. Package Leaflet" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "B. Package Leaflet" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>" ] ; fhir:emptyReason [ ( fhir:coding [ fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/list-empty-reason"^^xsd:anyURI ] ; fhir:code [ fhir:v "unavailable" ] ] ) ] ; ( fhir:section [ fhir:title [ fhir:v "Package leaflet: Information for the user" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "Package leaflet: Information for the user" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>" ] ] [ fhir:title [ fhir:v "What is in this leaflet" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "What is in this leaflet" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet</p><ol type=\"1\"><li>What LIBTAYO is and what it is used for</li><li>What you need to know before you are given LIBTAYO</li><li>How you are given LIBTAYO</li><li>Possible side effects</li><li>How to store LIBTAYO</li><li>Contents of the pack and other information</li></ol></div>" ] ] [ fhir:title [ fhir:v "1. What libtayo is and what it is used for" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "1. What libtayo is and what it is used for" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>LIBTAYO is an anti-cancer medicine that contains the active substance cemiplimab, which is a monoclonal antibody.</p><p>LIBTAYO is used in adults to treat:</p><ul><li>a type of skin cancer called advanced cutaneous squamous cell carcinoma (CSCC).</li><li>a type of skin cancer called advanced basal cell carcinoma (BCC) for which you have received treatment with a hedgehog pathway inhibitor and this treatment did not work well or was not well tolerated.</li><li>a type of lung cancer called advanced non-small cell lung cancer (NSCLC).</li><li>a type of cancer called cervical cancer that has worsened on or after chemotherapy.</li></ul><p>LIBTAYO may be given in combination with chemotherapy for NSCLC. It is important that you also read the package leaflets for the specific chemotherapy you may be receiving. If you have any questions about these medicines, ask your doctor.</p><p>LIBTAYO works by helping your immune system fight your cancer.</p></div>" ] ] [ fhir:title [ fhir:v "2. What you need to know before you take libtayo" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "2. What you need to know before you take libtayo" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>You should not be given LIBTAYO if:</p><ul><li>you are allergic to cemiplimab or any of the other ingredients of this medicine (listed in section 6). If you think you may be allergic, or you are not sure, talk to your doctor before you are given LIBTAYO.</li></ul><p>Warnings and precautions<br/>Talk to your doctor or nurse before you are given LIBTAYO if:</p><ul><li>you have an autoimmune disease (a condition where the body attacks its own cells)</li><li>you have had an organ transplant, or you have received or plan to receive a bone marrow transplant using bone marrow from another person (allogeneic haematopoietic stem cell transplant)</li><li>you have lung or breathing problems</li><li>you have liver problems</li><li>you have kidney problems</li><li>you have diabetes</li><li>you have any other medical conditions.</li></ul><p>If any of the above apply to you, or you are not sure, talk to your doctor or nurse before you are given LIBTAYO.</p><p>Look out for side effects LIBTAYO can cause some serious side effects that you need to tell your doctor about immediately. These problems may happen anytime during treatment or even after your treatment has ended. You may have more than one side effect at the same time.</p><p>These serious side effects include:</p><ul><li>Skin problems</li><li>Lung problems (pneumonitis)</li><li>Gut problems (colitis)</li><li>Liver problems (hepatitis)</li><li>Hormone gland problems - especially thyroid, pituitary, adrenal glands and the pancreas</li><li>Type 1 diabetes, including diabetic ketoacidosis (acid in the blood produced from diabetes)</li><li>Kidney problems (nephritis and kidney failure)</li><li>Central nervous system problems (such as meningitis)</li><li>Infusion-related reactions</li><li>Muscle problems (inflammation of the muscles called myositis)</li><li>Inflammation of the heart muscle (myocarditis)</li><li>A disease where the immune system makes too many of otherwise normal infection- fighting cells called histiocytes and lymphocytes that may cause various symptoms (haemophagocytic lymphohistiocytosis) (see Possible side effects for the list of signs and symptoms)</li><li>Problems in other parts of the body (see Possible side effects )</li></ul><p>Look out for these side effects while you are receiving LIBTAYO. See Possible side effects section in section 4. If you have any of these effects, talk to your doctor immediately.<br/>Your doctor may give you other medicines in order to stop more severe reactions and reduce your symptoms. Your doctor also may delay your next dose of LIBTAYO or stop your treatment.</p><p>Children and adolescents LIBTAYO should not be used in children and adolescents below 18 years of age.</p><p>Other medicines and LIBTAYO Tell your doctor if you are taking, have recently taken or might take any other medicines.</p><p>In particular, tell your doctor if you are taking or have ever taken any of the following medicines:</p><ul><li>a cancer medicine called idelalisib</li><li>medicines that make your immune system weak - examples include corticosteroids, such as prednisone. These medicines may interfere with the effect of LIBTAYO. However, once you are treated with LIBTAYO, your doctor may give you corticosteroids to reduce the side effects that you may have with LIBTAYO.</li></ul><p>Pregnancy<br/>If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before you are given this medicine.</p><ul><li>LIBTAYO can harm your unborn baby.</li><li>Tell your doctor immediately if you become pregnant while you are being treated with LIBTAYO.</li><li>If you are able to become pregnant, you must use an effective method of contraception to avoid becoming pregnant:</li></ul><p>while you are being treated with LIBTAYO and</p><p>for at least 4 months after the last dose.</p><ul><li>Talk to your doctor about the contraception methods that you must use during this time.</li></ul><p>Breast-feeding</p><ul><li>If you are breast-feeding or plan to breast-feed, ask your doctor for advice before you are given this medicine.</li><li>Do not breast-feed while you are being treated with LIBTAYO and for at least 4 months after the last dose.</li><li>It is not known if LIBTAYO passes into your breast milk.</li></ul><p>Driving and using machines LIBTAYO has no or minor influence on your ability to drive and use machines. If you feel tired, do not drive or use machines until you feel better.</p></div>" ] ] [ fhir:title [ fhir:v "3. How to take libtayo" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "3. How to take libtayo" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><ul><li>LIBTAYO will be given to you in a hospital or clinic - supervised by a doctor experienced in cancer treatment.</li><li>LIBTAYO is given as a drip into a vein (intravenous infusion).</li><li>The infusion will last about 30 minutes.</li><li>LIBTAYO is usually given every 3 weeks.</li></ul><p>How much you will receive</p><p>The recommended dose of LIBTAYO is 350 mg.</p><p>Your doctor will decide how much LIBTAYO you will receive and how many treatments you will need.</p><p>Your doctor will test your blood for certain side effects during your treatment.</p><p>If you miss an appointment Call your doctor as soon as possible to make another appointment. It is very important that you do not miss a dose of this medicine.</p><p>If you stop receiving LIBTAYO</p><p>Do not stop treatment of LIBTAYO unless you have discussed this with your doctor. This is because stopping your treatment may stop the effect of the medicine.</p><p>Patient Alert Card The information in this Package Leaflet can be found in the Patient Alert Card you have been given by your doctor. It is important that you keep this Patient Alert Card and show it to your partner or caregivers.</p><p>If you have any questions about your treatment, ask your doctor.</p></div>" ] ] [ fhir:title [ fhir:v "4. Possible side effects" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "4. Possible side effects" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Your doctor will discuss these with you and will explain the risks and benefits of your treatment.</p><p>LIBTAYO acts on your immune system and may cause inflammation in parts of your body (see the conditions listed in Look out for side effects in section 2). Inflammation may cause serious damage to your body and may need treatment or require you to stop treatment with LIBTAYO. Some inflammatory conditions may also lead to death.</p><p>Seek urgent medical attention if you have any of the following signs or symptoms, or if they get worse:</p><ul><li>Skin problems such as rash or itching, skin blistering or ulcers in mouth or other mucous membrane.</li><li>Lung problems (pneumonitis) such as new or worsening cough, being short of breath or chest pain.</li><li>Gut problems (colitis) such as frequent diarrhoea often with blood or mucus, more bowel movements than usual, stools that are black or tarry, and severe stomach (abdomen) pain or tenderness.</li><li>Liver problems (hepatitis) such as yellowing of your skin or the whites of your eyes, severe nausea or vomiting, pain on right side of your stomach (abdomen), feeling sleepy, dark urine (the colour of tea), bleeding or bruising more easily than normal and feeling less hungry than usual.</li><li>Hormone gland problems such as headache that will not go away or unusual headaches, fast heartbeat, increased sweating, feeling more cold or hot than usual, very tired, dizzy or fainting, weight gain or weight loss, feeling more hungry or thirsty than usual, hair loss, constipation, your voice gets deeper, very low blood pressure, passing water more often than usual, nausea or vomiting, stomach (abdomen) pain, changes in mood or behaviour (such as decreased sex drive, being irritable or forgetful).</li><li>Symptoms of type 1 diabetes or diabetic ketoacidosis such as feeling more hungry or thirsty than usual, needing to urinate more often, weight loss, feeling tired or feeling sick, stomach pain, fast and deep breathing, confusion, unusual sleepiness, a sweet smell to your breath, a sweet or metallic taste in your mouth, or a different odour to your urine or sweat.</li><li>Kidney problems (nephritis and kidney failure) such as passing water less often than usual, passing blood, swollen ankles and feeling less hungry than normal.</li><li>Infusion-related reactions (sometimes can be severe or life-threatening) such as chills, shaking or fever, itching or rash, flushing or swollen face, being short of breath or wheezing, feeling dizzy or feel like passing out and back or neck pain, nausea, vomiting or abdominal pain.</li><li>Problems in other parts of the body such as:</li></ul><p>Nervous system problems such as headache or stiff neck, fever, feeling tired or weak, chills, vomiting, confusion, memory problems or feeling sleepy, fits (seizures), seeing or hearing things that are not really there (hallucinations), severe muscle</p><p>weakness, tingling, numbness, weakness or burning pain in arms or legs, paralysis in the extremities</p><p>Muscle and joint problems such as joint pain or swelling, muscle pain, weakness or stiffness</p><p>Eye problems such as changes in eyesight, eye pain or redness, sensitivity to light</p><p>Heart and circulatory problems such as changes in heartbeat, heart beating fast, seeming to skip a beat or pounding sensation, chest pain, shortness of breath</p><p>Other: dryness in many parts of the body from mouth to eyes, nose, throat and the top layers of skin, bruises on the skin or bleeding, enlarged liver and/or spleen, lymph node enlargement</p><p>The following side effects have been reported in clinical trials of patients treated with cemiplimab alone:</p><p>Very common (may affect more than 1 in 10 people):</p><ul><li>feeling tired</li><li>muscle pain or bone pain</li><li>rash</li><li>diarrhoea (loose stools)</li><li>decreased number of red blood cells</li><li>nausea</li><li>feeling less hungry</li><li>itching</li><li>constipation</li><li>cough</li><li>stomach pain (abdominal pain)</li><li>upper respiratory tract infection.</li></ul><p>Common (may affect up to 1 in 10 people):</p><ul><li>vomiting</li><li>shortness of breath</li><li>fever</li><li>urinary tract infection</li><li>headache</li><li>swelling (oedema)</li><li>thyroid gland problems (hyperthyroidism and hypothyroidism)</li><li>high blood pressure</li><li>increased liver enzymes in blood</li><li>patches of thick, scaly, or crusty skin (actinic keratosis)</li><li>cough, inflammation of the lungs</li><li>infusion-related reactions</li><li>inflammation of the liver</li><li>inflammation of the intestines (diarrhoea, more bowel movements than usual, stools that are black or tarry, severe stomach (abdomen) pain or tenderness)</li><li>inflammation of the mouth</li><li>abnormal kidney function test</li><li>inflammation of the nerves causing tingling, numbness, weakness or burning pain of the arms or legs</li><li>inflammation of the kidneys.</li></ul><p>Uncommon (may affect up to 1 in 100 people):</p><ul><li>joint pain, swelling, polyarthritis and joint effusion</li><li>bruises on the skin or bleeding</li><li>inflammation of the thyroid</li><li>inflammation of the heart muscle, which may present as shortness of breath, irregular heartbeat, feeling tired or chest pain</li><li>decreased secretion of hormones produced by the adrenal glands</li><li>muscle weakness</li><li>inflammation of the pituitary gland situated at the base of the brain</li><li>inflammation of the covering of the heart</li><li>dryness in many parts of the body, from mouth to eyes, nose, throat and the top layers of skin</li><li>inflammation of the muscles which may include muscle pain or weakness (myositis) and could be associated with a rash (dermatomyositis).</li><li>inflammation of the stomach lining</li><li>muscle pain or stiffness (polymyalgia rheumatica).</li></ul><p>Rare (may affect up to 1 in 1000 people):</p><ul><li>inflammation of brain and spinal cord membranes, which can be caused by infection</li><li>type 1 diabetes that may include feeling more hungry or thirsty than usual, needing to urinate more often, weight loss, and feeling tired, or diabetic ketoacidosis</li><li>eye pain, irritation, itchiness or redness; uncomfortable sensitivity to light</li><li>a temporary inflammation of the nerves that causes pain, weakness, and paralysis in the extremities</li><li>a condition in which the muscles become weak and tire easily, muscle pain.</li></ul><p>Other side effects that have been reported (frequency not known):</p><ul><li>organ transplant rejection</li><li>inflammation of the bladder. Signs and symptoms may include frequent and/or painful urination, urge to pass urine, blood in urine, pain or pressure in the lower abdomen</li><li>haemophagocytic lymphohistiocytosis. A disease in which your immune system makes too many of otherwise normal infection fighting cells called histiocytes and lymphocytes. Symptoms may include enlarged liver and/or spleen, skin rash, lymph node enlargement, breathing problems, easy bruising, kidney and heart problems.</li></ul><p>The following side effects have been reported in clinical trials of patients treated with cemiplimab in combination with chemotherapy:</p><p>Very common (may affect more than 1 in 10 people):</p><ul><li><p>decreased number of red blood cells</p></li><li><p>hair loss</p></li><li><p>muscle pain or bone pain</p></li><li><p>nausea</p></li><li><p>feeling tired</p></li><li><p>inflammation of the nerves causing tingling, numbness, weakness or burning pain of the arms or legs</p></li><li><p>high blood sugar</p></li><li><p>feeling less hungry</p></li><li><p>increased liver enzymes in blood</p></li><li><p>decrease in the number of white blood cell (neutrophils)</p></li><li><p>constipation</p></li><li><p>decrease in the number of platelets</p></li><li><p>shortness of breath</p></li><li><p>rash</p></li><li><p>vomiting</p></li><li><p>weight loss</p></li><li><p>trouble sleeping</p></li><li><p>diarrhoea (loose stools)</p></li><li><p>low levels in the blood of a protein called albumin .</p></li></ul><p>Common (may affect up to 1 in 10 people):</p><ul><li>abnormal kidney function test</li><li>thyroid gland problems (hyperthyroidism and hypothyroidism)</li><li>cough, inflammation of the lungs</li><li>itching</li><li>inflammation of the kidneys</li><li>inflammation of the intestines (diarrhoea, more bowel movements than usual, stools that are black or tarry, severe stomach (abdomen) pain or tenderness)</li><li>joint pain, swelling, polyarthritis and joint effusion.</li></ul><p>Uncommon (may affect up to 1 in 100 people):</p><ul><li>inflammation of the thyroid</li><li>infusion-related reactions</li><li>type 1 diabetes that may include feeling more hungry or thirsty than usual, needing to urinate more often, weight loss, and feeling tired.</li></ul><p>Reporting of side effects If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>" ] ] [ fhir:title [ fhir:v "5. How to store libtayo" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "5. How to store libtayo" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and vial after EXP. The expiry date refers to the last day of that month.</p><p>Store in a refrigerator (2 C to 8 C).</p><p>Do not freeze.</p><p>Store in the original container in order to protect from light.</p><p>From a microbiological point of view the prepared solution for infusion should be used immediately. If diluted solution is not administered immediately, in-use storage times and conditions prior to use are the responsibility of the user.</p><p>Chemical and physical in-use stability has been demonstrated as follows:</p><ul><li>at room temperature up to 25 C for no more than 8 hours from the time of infusion preparation to the end of infusion. Or</li><li>under refrigeration at 2 C to 8 C for no more than 10 days from the time of infusion preparation to the end of infusion. Allow the diluted solution to come to room temperature prior to administration.</li></ul><p>Do not store any unused portion of the infusion solution for re-use. Any unused portion of the infusion solution should not be re-used and should be disposed in accordance with local requirements.</p></div>" ] ] [ fhir:title [ fhir:v "6. Contents of the pack and other information" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "6. Contents of the pack and other information" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What LIBTAYO contains</p><p>The active substance is cemiplimab:</p><ul><li>One ml of concentrate contains 50 mg of cemiplimab.</li><li>Each vial contains 350 mg cemiplimab in 7 ml of concentrate.</li></ul><p>The other ingredients are L-Histidine, L-Histidine monohydrochloride monohydrate, L-proline, sucrose, polysorbate 80 and water for injections.</p><p>What LIBTAYO looks like and contents of the pack</p><p>LIBTAYO concentrate for solution for infusion (sterile concentrate) is supplied as a clear to slightly opalescent, colourless to pale yellow sterile solution that may contain trace amounts of translucent to white particles.</p><p>Each carton contains 1 glass vial with 7 ml of concentrate.</p><p>Marketing Authorisation Holder<br/>Regeneron Ireland Designated Activity Company (DAC) One Warrington Place,<br/>Dublin 2, D02 HHIreland</p><p>Manufacturer Regeneron Ireland DAC Raheen Business Park Limerick Ireland</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien Regeneron Ireland DAC T l/Tel: 0800 89Lietuva Medison Pharma Lithuania UAB Tel: 8 800 33<br/>Medison Pharma Bulgaria Ltd. .: 8002100Luxembourg/Luxemburg Regeneron Ireland DAC T l/Tel: 8007-9 esk republika Medison Pharma s.r.o. Magyarorsz g Medison Pharma Hungary Kft</p><p>Tel: 800 050 Tel.: 06-809-93Danmark Regeneron Ireland DAC Tlf: 80 20 03 Malta Genesis Pharma (Cyprus) Ltd Tel: 080065Deutschland Regeneron GmbH Tel.: 0800 330 4Nederland Regeneron Ireland DAC Tel: 0800 020 0Eesti Medison Pharma Estonia O<br/>Tel: 800 004 4Norge Regeneron Ireland DAC Tlf: 8003 15<br/>. . : 00800 44146 sterreich Regeneron Ireland DAC Tel: 01206094Espa a sanofi-aventis, S.A.<br/>Tel: 0900031Polska Medison Pharma Sp. z o.o. Tel.: 0800 080 France Regeneron France SAS T l: 080 554 3Portugal Regeneron Ireland DAC Tel: 800783Hrvatska<br/>Medison Pharma d.o.o. Tel: 800 787 Rom nia Medison Pharma SRL Tel: 0800 400Ireland Regeneron Ireland DAC Tel: 01800800Slovenija Medison Pharma d.o.o. Tel: 386 800 83 sland Regeneron Ireland DAC<br/>S mi: 354 800 4Slovensk republika Medison Pharma s.r.o. Tel: 0800 123 Italia Regeneron Italy S.r.l. Tel: 800180Suomi/Finland Regeneron Ireland DAC<br/>Puh/Tel: 0800 772<br/>Genesis Pharma (Cyprus) Ltd : 0800 925 Sverige Regeneron Ireland DAC Tel: 0201 604Latvija Medison Pharma Latvia SIA Tel: 371 8000 5United Kingdom (Northern Ireland) Regeneron Ireland DAC<br/>Tel: 0 800 917 7This leaflet was last revised in</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>" ] ] ) ] ) . # <MedicinalProductDefinition/mpcfcde91a66ec9c44e54756602bc42482> a fhir:MedicinalProductDefinition ; fhir:id [ fhir:v "mpcfcde91a66ec9c44e54756602bc42482"] ; # fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"^^xsd:anyURI ; fhir:link <http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi> ] ) ] ; # fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mpcfcde91a66ec9c44e54756602bc42482\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mpcfcde91a66ec9c44e54756602bc42482</b></p><a name=\"mpcfcde91a66ec9c44e54756602bc42482\"> </a><a name=\"hcmpcfcde91a66ec9c44e54756602bc42482\"> </a><a name=\"mpcfcde91a66ec9c44e54756602bc42482-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/19/1376/001</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: LIBTAYO 350 mg concentrate for solution for infusion.</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>" ] ; # fhir:identifier ( [ fhir:system [ fhir:v "http://ema.europa.eu/identifier"^^xsd:anyURI ] ; fhir:value [ fhir:v "EU/1/19/1376/001" ] ] ) ; # fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/medicinal-product-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "MedicinalProduct" ] ; fhir:display [ fhir:v "Medicinal Product" ] ] ) ] ; # fhir:domain [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/medicinal-product-domain"^^xsd:anyURI ] ; fhir:code [ fhir:v "Human" ] ; fhir:display [ fhir:v "Human use" ] ] ) ] ; # fhir:status [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/publication-status"^^xsd:anyURI ] ; fhir:code [ fhir:v "active" ] ; fhir:display [ fhir:v "active" ] ] ) ] ; # fhir:legalStatusOfSupply [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000072084" ] ; fhir:display [ fhir:v "Medicinal product subject to medical prescription" ] ] ) ] ; # fhir:name ( [ fhir:productName [ fhir:v "LIBTAYO 350 mg concentrate for solution for infusion." ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000001" ] ; fhir:display [ fhir:v "Full name" ] ] ) ] ; ( fhir:part [ fhir:part [ fhir:v "nan" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000002" ] ; fhir:display [ fhir:v "Invented name part" ] ] ) ] ] [ fhir:part [ fhir:v "nan" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000003" ] ; fhir:display [ fhir:v "Scientific name part" ] ] ) ] ] [ fhir:part [ fhir:v "nan" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000004" ] ; fhir:display [ fhir:v "Strength part" ] ] ) ] ] [ fhir:part [ fhir:v "nan" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000005" ] ; fhir:display [ fhir:v "Pharmaceutical dose form part" ] ] ) ] ] ) ; ( fhir:usage [ fhir:country [ ( fhir:coding [ fhir:system [ fhir:v "urn:iso:std:iso:3166"^^xsd:anyURI ] ; fhir:code [ fhir:v "EU" ] ; fhir:display [ fhir:v "EU" ] ] ) ] ; fhir:jurisdiction [ ( fhir:coding [ fhir:system [ fhir:v "urn:iso:std:iso:3166"^^xsd:anyURI ] ; fhir:code [ fhir:v "EU" ] ; fhir:display [ fhir:v "EU" ] ] ) ] ; fhir:language [ ( fhir:coding [ fhir:system [ fhir:v "urn:ietf:bcp:47"^^xsd:anyURI ] ; fhir:code [ fhir:v "en" ] ; fhir:display [ fhir:v "en" ] ] ) ] ] ) ] ) . #
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
